WO2025062334 - 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2025/062334
Publication Date
27.03.2025
International Application No.
PCT/IB2024/059102
International Filing Date
19.09.2024
Title **
[English]
4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER
[French]
DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER
Applicants **
BEONE MEDICINES I GMBH
BEONE PHARMACEUTICAL (SUZHOU) CO., LTD.
Inventors
HUO, Changxin
ZHAO, Yu
WANG, Yucheng
LIU, Huaqing
WANG, Zhiwei
Priority Data
PCT/CN2023/120162
20.09.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3413 | |
| EPO | Filing, Examination, Granting | 14729 | |
| Japan | Filing, Examination, Granting | 2246 | |
| South Korea | Filing, Examination, Granting | 2259 | |
| USA | Filing, Examination, Granting | 6690 |
Total:
29,337
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are compounds of formula (I) used as inhibitors of cyclin-dependent kinases for treating cancer[French]
L'invention concerne des composés de formule (I) utilisés comme inhibiteurs de kinases dépendantes des cyclines pour le traitement du cancer.